AlphaTON Capital Corp (ALP) Prix

AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. The firm is focused on building and managing a strategic reserve of The Open Network (TON) tokens and developing the Telegram ecosystem. The firm implements a treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, the Company provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion user platform. The company is also advancing therapies that target known checkpoint resistance pathways to achieve durable treatment response and improve quality of life for patients. The firm engages in the drug development process and provides strategic counsel to guide development of immunotherapy assets and asset combinations.